10-Q: APx Acquisition Corp. I Faces Delisting and Going Concern Doubts Amidst Mounting Losses and Business Combination Hurdles

APx Acquisition Corp. I reported a significant net loss and increased liabilities for Q1 2025, raising substantial doubt about its ability to continue as a going concern following its delisting from Nasdaq and the termination of a key acquisition target.

Summary

• APx Acquisition Corp. I (APXIF), a blank check company, reported a net loss of $3,676,898 for the three months ended March 31, 2025, significantly wider than the $2,249,261 loss for the same period in 2024.
• The company's Class A ordinary shares were delisted from Nasdaq on March 31, 2025, and now trade on the Pink Open Market of the OTC under the symbol APXIF. Warrants and units were also suspended from trading and were delisted by May 18, 2025.
• Management has raised "substantial doubt" about the company's ability to continue as a going concern due to insufficient cash flows and the mandatory liquidation if a business combination is not completed by December 9, 2025.
• The proposed business combination with OmnigenicsAI Corp. is still intended, but the acquisition of MultiplAI Health Ltd., a key component, was terminated on August 27, 2024.
• The company's cash balance was critically low at $72 as of March 31, 2025, down from $120 at December 31, 2024.
• Total liabilities surged to $9,913,907 as of March 31, 2025, from $6,171,535 at December 31, 2024, primarily due to a significant increase in warrant liabilities.
• The company's accumulated deficit deepened to $(9,914,266) as of March 31, 2025, from $(6,171,846) at December 31, 2024.
• Disclosure controls and procedures were deemed "not effective" as of March 31, 2025, due to identified material weaknesses in internal control over financial reporting.

Sentiment

Score: 2

Explanation: The company faces severe challenges, including significant financial losses, critical liquidity issues, delisting from Nasdaq, and substantial doubt about its ability to continue as a going concern. The termination of a key acquisition target and identified material weaknesses in internal controls further compound the negative outlook, despite ongoing efforts for a business combination and secured promissory notes.

Positives

• Operating expenses decreased significantly to $351,503 for the three months ended March 31, 2025, compared to $1,305,094 for the same period in 2024.
• The company has secured additional financing through promissory notes from related parties, including $1,743,499 outstanding under the Working Capital Promissory Note and $1,158,037 under the Bioceres Notes as of March 31, 2025.
• A backstop agreement is in place with Theo I SCSp, obligating them to provide up to $10,000,000 to ensure sufficient cash for the business combination, subject to certain conditions.

Negatives

• Net loss widened to $3,676,898 for Q1 2025 from $2,249,261 for Q1 2024.
• Cash balance is critically low at $72 as of March 31, 2025.
• Working capital deficit increased to $5,168,585 as of March 31, 2025.
• Total liabilities increased substantially to $9,913,907 as of March 31, 2025, driven by a $3,339,250 loss from the change in fair value of warrant liabilities.
• Interest earned on investments in the Trust Account significantly decreased to $65,522 in Q1 2025 from $813,333 in Q1 2024, reflecting reduced funds in the Trust Account due to prior redemptions.
• The company's Class A ordinary shares, units, and warrants have been delisted or are in the process of delisting from Nasdaq.
• The acquisition of MultiplAI Health Ltd., a key part of the proposed business combination, was terminated.
• Management concluded that disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.
• The company faces "substantial doubt" about its ability to continue as a going concern.

Risks

• **Going Concern Uncertainty**: Substantial doubt about the company's ability to continue as a going concern due to insufficient cash flows and the mandatory liquidation if a business combination is not consummated by December 9, 2025.
• **Business Combination Risk**: There is no assurance that the company will be able to successfully effect a Business Combination, which is a critical condition for its continued existence.
• **Delisting Risk**: The company's securities have been delisted from Nasdaq, which may impact liquidity and investor interest. Nasdaq approval of OmnigenicsAI's initial listing application is a condition to the Business Combination, and there is no guarantee it will be approved.
• **Liquidity Risk**: Critically low cash balance ($72 as of March 31, 2025) and a significant working capital deficit ($5,168,585), requiring reliance on promissory notes and potential future capital.
• **Market Volatility and Geopolitical Instability**: Global economic consequences from military conflicts (Ukraine, Middle East) may adversely affect the ability to consummate a Business Combination or the operations of a target business, and impact the ability to raise equity and debt financing.
• **Internal Control Weaknesses**: Material weaknesses in internal control over financial reporting were identified, related to warrant liabilities, related party gains, equity classification, cash flow statement classification, and accuracy/completeness of accrued expenses, interest receivable, and redemption value of ordinary shares.
• **Warrant Valuation Risk**: The fair value of warrant liabilities is subject to re-measurement, leading to non-cash gains or losses that can significantly impact net loss.
• **Redemption Risk**: Prior public shareholder redemptions have significantly reduced the funds in the Trust Account and the number of outstanding public shares, impacting the capital available for a business combination.
• **Sponsor Indemnification Risk**: Uncertainty whether the Sponsor has sufficient funds to satisfy its indemnity obligations for claims by third parties that reduce the Trust Account below $10.00 per Public Share.

Future Outlook

The company intends to proceed with its efforts to consummate the initial Business Combination with OmnigenicsAI Corp. by the extended deadline of December 9, 2025. However, Nasdaq approval of OmnigenicsAI's initial listing application is a condition to the Business Combination, and there is no guarantee of approval, which may delay or ultimately prevent the consummation. The company will remain a reporting entity under the Securities Exchange Act of 1934 despite delisting from Nasdaq.

Management Comments

• "Management has determined that the mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution as well as insufficient cash flows raises substantial doubt about the Companys ability to continue as a going concern."
• "Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective, as of March 31, 2025, because of material weaknesses in our internal control over financial reporting."
• "The Companys management has expended, and will continue to expend, a substantial amount of effort and resources for the remediation and improvement of our internal control over financial reporting."

Industry Context

As a Special Purpose Acquisition Company (SPAC), APx Acquisition Corp. I operates in a highly time-sensitive and capital-intensive segment of the financial market. The company's challenges, including significant shareholder redemptions, delisting from a major exchange (Nasdaq), and the termination of a key acquisition target (MultiplAI Health Ltd.), reflect broader difficulties faced by many SPACs in the current market environment. The inability to secure a business combination within the initial timeframe and the subsequent need for multiple extensions, coupled with a substantial increase in warrant liabilities, highlight the inherent risks and complexities of the SPAC model, especially when market conditions become less favorable for de-SPAC transactions and new listings.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The Sponsor (APx Cap Sponsor Group I, LLC) initially purchased Founder Shares for $25,000 and Private Placement Warrants for $8,950,000.
• On September 8, 2023, the Sponsor transferred 3,342,188 Founder Shares and 6,936,250 Private Placement Warrants to Templar, LLC and its designees (the Purchaser) for $1.00 plus an agreement to advance up to $50,000 for Exchange Act filing obligations. The Sponsor retained 970,312 Founder Shares and 2,013,750 Private Placement Warrants.
• The company issued an unsecured Working Capital Promissory Note to Templar (a related party) for up to $2,000,000, with $1,743,499 outstanding as of March 31, 2025.
• The company issued the Bioceres Note ($446,000) and Second Bioceres Note (up to $712,038) to Bioceres LLC, an indirect shareholder of OmnigenicsAI Corp., the business combination counterparty.
• An administrative services agreement with an affiliate of the Sponsor for up to $10,000 per month was terminated as of August 30, 2023.

Stakeholder Impact

• **Shareholders**: Significant negative impact due to delisting from Nasdaq, substantial net losses, increased liabilities, and uncertainty regarding the consummation of the business combination. Public shareholders who redeemed shares received a pro rata portion of the Trust Account.
• **Investors (Warrant Holders)**: Warrants have been suspended from trading and will be delisted, potentially rendering them worthless if a business combination is not completed or if the company liquidates.
• **Management/Employees**: Faces pressure to complete the business combination and address internal control deficiencies to ensure the company's continuity.
• **Creditors**: Promissory notes from related parties (Sponsor, Bioceres LLC) are outstanding, with repayment contingent on the business combination.
• **Prospective Target (OmnigenicsAI Corp.)**: The business combination is contingent on Nasdaq listing approval for OmnigenicsAI, which is uncertain given APx's delisting. The termination of the MultiplAI acquisition also changes the scope of the deal.

Next Steps

• Proceed with efforts to consummate the initial Business Combination with OmnigenicsAI Corp.
• Seek Nasdaq approval for OmnigenicsAI's initial listing application, which is a condition for the Business Combination.
• Remediate and improve internal control over financial reporting to address identified material weaknesses.
• Continue to operate as a reporting entity under the Securities Exchange Act of 1934 despite delisting.

Key Dates

Recommendation

Keywords

SPAC, Blank Check Company, APx Acquisition Corp. I, 10-Q, Quarterly Report, SEC Filing, Business Combination, OmnigenicsAI Corp., Delisting, Nasdaq, OTC Markets, Going Concern, Financial Results, Net Loss, Warrant Liabilities, Liquidity, Promissory Notes, Capital Raise, Internal Controls, Risk Factors, Shareholder Redemption, Trust Account